PRB2 and neoplasm: In a successive study, we found that CP7-PEG-b-PLL/DOX showed better inhibitory activity on A549 tumor models both in vitro and in vivo than DOX alone, which is obviously due to the excellent targeting effect of CP7 to A549 cells [21].